Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc.
Your view on MTNB
Overview
What the company does, where it operates, and who runs it.
About Matinas BioPharma Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jerome D. Jabbour
- Headquarters
- 1545 Route 206 South, Bedminster, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jerome D. Jabbour
- Headquarters
- 1545 Route 206 South, Bedminster, NJ, US
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology.
The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions.
The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.
In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Matinas BioPharma Holdings, Inc., and the rating behind it. MTNB last traded at $0.18; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Matinas BioPharma Holdings, Inc.. Starting points for Matinas BioPharma Holdings, Inc.: EPS -$1.14, beta 1.70 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Matinas BioPharma Holdings, Inc.. Matinas BioPharma Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Matinas BioPharma Holdings, Inc.. Trailing twelve-month EPS for Matinas BioPharma Holdings, Inc. stands at -$1.14. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Matinas BioPharma Holdings, Inc.. Matinas BioPharma Holdings, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Matinas BioPharma Holdings, Inc. valued side by side against its closest peers. Matinas BioPharma Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Matinas BioPharma Holdings, Inc., and how their positions are changing. At a $1.2M market value, institutional positions materially move Matinas BioPharma Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Matinas BioPharma Holdings, Inc. executives and directors. Shares of Matinas BioPharma Holdings, Inc. have traded between $0.47 and $3.09 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Matinas BioPharma Holdings, Inc.. Matinas BioPharma Holdings, Inc. is a $1.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Matinas BioPharma Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Matinas BioPharma Holdings, Inc.. Coverage tracks Matinas BioPharma Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.